280 related articles for article (PubMed ID: 15625915)
1. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
Olie RA; Hafner C; Küttel R; Sigrist B; Willers J; Dummer R; Hall J; Stahel RA; Zangemeister-Wittke U
J Invest Dermatol; 2002 Mar; 118(3):505-12. PubMed ID: 11874491
[TBL] [Abstract][Full Text] [Related]
4. Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide.
Olie RA; Hall J; Natt F; Stahel RA; Zangemeister-Wittke U
Biochim Biophys Acta; 2002 Jun; 1576(1-2):101-9. PubMed ID: 12031489
[TBL] [Abstract][Full Text] [Related]
5. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
[TBL] [Abstract][Full Text] [Related]
6. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells.
Simões-Wüst AP; Olie RA; Gautschi O; Leech SH; Häner R; Hall J; Fabbro D; Stahel RA; Zangemeister-Wittke U
Int J Cancer; 2000 Aug; 87(4):582-90. PubMed ID: 10918201
[TBL] [Abstract][Full Text] [Related]
8. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
Lebedeva I; Raffo A; Rando R; Ojwang J; Cossum P; Stein CA
J Urol; 2001 Aug; 166(2):461-9. PubMed ID: 11458048
[TBL] [Abstract][Full Text] [Related]
11. p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide.
Strasberg Rieber M; Zangemeister-Wittke U; Rieber M
Clin Cancer Res; 2001 May; 7(5):1446-51. PubMed ID: 11350916
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide inhibition of Bcl-xL and Bid expression in liver regulates responses in a mouse model of Fas-induced fulminant hepatitis.
Zhang H; Taylor J; Luther D; Johnston J; Murray S; Wyatt JR; Watt AT; Koo S; York-DeFalco C; Stecker K; Dean NM
J Pharmacol Exp Ther; 2003 Oct; 307(1):24-33. PubMed ID: 12893848
[TBL] [Abstract][Full Text] [Related]
14. Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling.
Zangemeister-Wittke U
Ann N Y Acad Sci; 2003 Dec; 1002():90-4. PubMed ID: 14751826
[TBL] [Abstract][Full Text] [Related]
15. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.
Taylor JK; Zhang QQ; Wyatt JR; Dean NM
Nat Biotechnol; 1999 Nov; 17(11):1097-100. PubMed ID: 10545916
[TBL] [Abstract][Full Text] [Related]
16. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
Smythe WR; Mohuiddin I; Ozveran M; Cao XX
J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
[TBL] [Abstract][Full Text] [Related]
17. [The effects of antisense oligonucleotides bcl-2/bcl-xl and bcl-2 on proliferation and apoptosis of breast cancer cells].
Ma C; Xie JW; Kuang AR; Huang R; Tang GS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):780-3. PubMed ID: 19950582
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death.
Jiang Z; Zheng X; Rich KM
J Neurochem; 2003 Jan; 84(2):273-81. PubMed ID: 12558990
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
20. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]